Development of Sustained Release Baricitinib Loaded Lipid-Polymer Hybrid Nanoparticles with Improved Oral Bioavailability

• Published in: Molecules (Basel, Switzerland) Switzerland), 2022-01, Vol.27 (1), p.168
• Main Authors: Anwer, Md Khalid, Ali, Essam A, Iqbal, Muzaffar, Ahmed, Mohammed Muqtader, Aldawsari, Mohammed F, Saqr, Ahmed Al, Ansari, Mohd Nazam, Aboudzadeh, M Ali
• Format: Article
• Language: English
• Subjects: Administration, Oral; Animals; Arthritis; Azetidines - administration & dosage; Azetidines - chemistry; Azetidines - pharmacokinetics; baricitinib; Bioavailability; Biological Availability; Chemical Sciences; Controlled release; Coronaviruses; COVID-19; Drug Carriers - chemistry; Drug delivery; Drug delivery systems; Drug Liberation; Drugs; Efficiency; encapsulation; Entrapment; Enzyme inhibitors; hybrid nanoparticles; In vivo methods and tests; Janus kinase; Lipids; Liposomes - chemistry; Male; Nanoparticles; Nanoparticles - chemistry; Oral administration; Particle size; Permeability; Pharmacokinetics; Pharmacology; Physicochemical properties; poly( d , l -lactide-coglycolide); Polydispersity; Polyethylene glycol; Polymers; Polymers - chemistry; Purines - administration & dosage; Purines - chemistry; Purines - pharmacokinetics; Pyrazoles - administration & dosage; Pyrazoles - chemistry; Pyrazoles - pharmacokinetics; Rats; Rats, Wistar; Regulatory approval; Rheumatoid arthritis; Stearin; Sulfonamides - administration & dosage; Sulfonamides - chemistry; Sulfonamides - pharmacokinetics; Sustained release; Zeta potential
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules27010168

Baricitinib (BTB) is an orally administered Janus kinase inhibitor, therapeutically used for the treatment of rheumatoid arthritis. Recently it has also been approved for the treatment of COVID-19 infection. In this study, four different BTB-loaded lipids (stearin)-polymer (Poly(d,l-lactide-co-glycolide)) hybrid nanoparticles (B-PLN1 to B-PLN4) were prepared by the single-step nanoprecipitation method. Next, they were characterised in terms of physicochemical properties such as particle size, zeta potential (ζP), polydispersity index (PDI), entrapment efficiency (EE) and drug loading (DL). Based on preliminary evaluation, the B-PLN4 was regarded as the optimised formulation with particle size (272 ± 7.6 nm), PDI (0.225), ζP (-36.5 ± 3.1 mV), %EE (71.6 ± 1.5%) and %DL (2.87 ± 0.42%). This formulation (B-PLN4) was further assessed concerning morphology, in vitro release, and in vivo pharmacokinetic studies in rats. The in vitro release profile exhibited a sustained release pattern well-fitted by the Korsmeyer-Peppas kinetic model (R = 0.879). The in vivo pharmacokinetic data showed an enhancement (2.92 times more) in bioavailability in comparison to the normal suspension of pure BTB. These data concluded that the formulated lipid-polymer hybrid nanoparticles could be a promising drug delivery option to enhance the bioavailability of BTB. Overall, this study provides a scientific basis for future studies on the entrapment efficiency of lipid-polymer hybrid systems as promising carriers for overcoming pharmacokinetic limitations.